Exelixis (EXEL) Insider Michael Morrissey Sells 90,000 Shares

Exelixis (NASDAQ:EXEL) insider Michael Morrissey sold 90,000 shares of the stock in a transaction that occurred on Wednesday, April 11th. The stock was sold at an average price of $20.78, for a total value of $1,870,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

NASDAQ EXEL opened at $20.87 on Friday. Exelixis has a 1-year low of $18.03 and a 1-year high of $32.50. The company has a market capitalization of $6,191.27, a P/E ratio of 40.92 and a beta of 2.10.

How to Become a New Pot Stock Millionaire

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The firm had revenue of $120.10 million during the quarter, compared to the consensus estimate of $120.25 million. During the same period last year, the business posted $0.12 EPS. Exelixis’s quarterly revenue was up 54.8% on a year-over-year basis. equities analysts predict that Exelixis will post 0.58 earnings per share for the current fiscal year.

A number of analysts have weighed in on the company. William Blair reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, April 11th. BidaskClub cut Exelixis from a “sell” rating to a “strong sell” rating in a report on Wednesday, April 4th. Cann reissued a “buy” rating and issued a $40.00 price target on shares of Exelixis in a report on Tuesday, March 20th. Zacks Investment Research raised Exelixis from a “sell” rating to a “hold” rating in a report on Monday, March 19th. Finally, TheStreet cut Exelixis from a “b” rating to a “c+” rating in a report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. Exelixis currently has a consensus rating of “Hold” and an average price target of $34.10.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXEL. American Century Companies Inc. increased its stake in Exelixis by 426.4% in the 4th quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock valued at $44,686,000 after purchasing an additional 1,190,691 shares in the last quarter. Jennison Associates LLC increased its stake in Exelixis by 38.1% in the 4th quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock valued at $128,554,000 after purchasing an additional 1,167,758 shares in the last quarter. Smith Asset Management Group LP purchased a new position in Exelixis during the fourth quarter worth $26,323,000. Caisse DE Depot ET Placement DU Quebec purchased a new position in Exelixis during the fourth quarter worth $17,480,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Exelixis by 34.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,843,129 shares of the biotechnology company’s stock worth $56,031,000 after buying an additional 471,023 shares in the last quarter. 80.49% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Exelixis (EXEL) Insider Michael Morrissey Sells 90,000 Shares” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://weekherald.com/2018/04/22/michael-morrissey-sells-90000-shares-of-exelixis-exel-stock.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply